DrugPatentWatch Database Preview

Details for Patent: 6,268,343

« Back to Dashboard

Which drugs does patent 6,268,343 protect, and when does it expire?

Patent 6,268,343 protects SAXENDA, VICTOZA, and XULTOPHY 100/3.6, and is included in three NDAs.

This patent has eighty-nine patent family members in twenty-three countries.

Summary for Patent: 6,268,343

Title:	Derivatives of GLP-1 analogs
Abstract:	The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.
Inventor(s):	Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (K.o slashed.benhavn K, DK), Nielsen; Per Franklin (V.ae butted.rl.o slashed.se, DK), Kaarsholm; Niels C. (Vanl.o slashed.se, DK), Olsen; Helle Birk (Aller.o slashed.d, DK), Bj.o slashed.rn; S.o slashed.ren Erik (Lyngby, DK), Pedersen; Freddy Zimmerdahl (V.ae butted.rl.o slashed.se, DK), Madsen; Kjeld (V.ae butted.rl.o slashed.se, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	09/258,750
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,268,343
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,268,343
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,268,343

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes			Y	Y		METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes			Y	Y		A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo	XULTOPHY 100/3.6	insulin degludec; liraglutide	SOLUTION;SUBCUTANEOUS	208583-001	Nov 21, 2016		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 6,268,343

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	0931/96	Aug 30, 1996
Denmark	1259/96	Nov 08, 1996
Denmark	1470/96	Dec 20, 1996
Denmark	0263/98	Feb 27, 1998

International Family Members for US Patent 6,268,343

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	265224
Austria	269103
Austria	356830
Austria	466026